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Microphthalmia Associated Transcription Factor Is a Target
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In B16 melanoma cells, cyclic adenosine monopho-
sphate inhibits the phosphatidylinositol-3-kinase and
the phosphatidylinositol-3-kinase inhibitor, LY294002,
stimulates melanogenesis. However, the molecular
mechanisms, by which phosphatidylinositol-3-kinase
inhibition increases melanogenesis remained to be
identi¢ed. In this study, we show that LY294002 up-reg-
ulates the expression of the melanogenic enzymes, tyr-
osinase and Tyrp1, through a transcriptional mechanism
that involves microphthalmia associated transcription
factor, a basic helix-loop-helix transcription factor,
which plays a key role in melanocyte survival and dif-
ferentiation. Further, we observe that LY294002 in-
creases the intracellular content of microphthalmia
associated transcription factor, thereby demonstrating
that microphthalmia associated transcription factor is
also a convergence point of the phosphatidylinositol-3-
kinase signaling pathway. Finally, our results indicate
that LY294002 controls microphthalmia associated tran-
scription factor at the transcriptional level through dis-
tal regulatory element that remain to be identi¢ed.
Interestingly, we have recently reported that cAMP-ele-
vating agents, through a phosphatidylinositol-3-kinase/
AKT inhibition and a glycogen synthase kinase 3b
activation, may stimulate microphthalmia associated
transcription factor binding to its target sequence,
suggesting that inhibition of the phosphatidylinositol-
3-kinase is implicated in the stimulation of melanogen-
esis at di¡erent levels. Thus, the results presented in this
report strengthen the importance of the phosphatidyli-
nositol-3-kinase pathway in the regulation of mela-
nogenesis and emphasize the complexity of the cyclic
adenosine monophosphate signaling that controls mela-
nocyte di¡erentiation and melanogenesis. Key words:
cyclic adenosine monophosphate/microphthalmia associated
transcription factor /phosphatidylinositol-3-kinase/tyrosinase/
TYRP1. J Invest Dermatol 121:831 ^836, 2003
I
n mammals, pigmentation results from the synthesis and
distribution of melanin in the skin, hair bulbs, and eyes.
Melanin synthesis or melanogenesis occurs in melanocytes
through an enzymatic process, catalyzed by tyrosinase and
tyrosinase-related protein 1 (Tyrp1), which converts tyro-
sine to melanin pigments (Hearing, 1987; Prota, 1988; Jimenez-
Cervantes et al, 1994; Kobayashi et al, 1994). In vivo, these pigments
play a crucial photoprotective role against the carcinogenous ef-
fects of ultraviolet radiation of the solar light.
Compelling evidence has demonstrated the key role of the
melanotropic hormone a-melanocyte-stimulating hormone and
adrenocorticotropic hormone in the control of pigmentation.
a-melanocyte-stimulating hormone and adrenocorticotropic
hormone bind to the Gas-coupled MC1 receptor (MC1R) that leads
to adenylate cyclase activation, elevation of the intracellular cyclic
adenosine monophosphate (cAMP) content, and activation of
protein kinase A (PKA). Patients in which the cAMP/PKA path-
way has been altered, present skin pigmentation defects, thereby
demonstrating the importance of the cAMP/PKA pathway in the
regulation of melanogenesis (Schwindinger et al, 1992; Kirschner
et al, 2000). In vitro, the melanogenic e¡ects of a-melanocyte-sti-
mulating hormone can be mimicked by pharmacologic agents
such as forskolin, a direct activator of adenylate cyclase (Englaro
et al, 1995).We have previously shown that cAMP-elevating agents
increase the expression of the melanogenic enzymes, tyrosinase
and Tyrp1, by stimulating the transcription of their cognate
genes. We also reported that the M-box (AGTCATGTGCT), a
highly conserved DNA sequence, identi¢ed in the promoter of
these enzymes, is essential for their cAMP responsiveness. The
M-box binds MITF (microphthalmia-associated transcription
factor), a transcription factor of the basic-helix-loop-helix-
leucine-zipper family (b-HLH-LZ) that plays a crucial part in
melanocyte development (Hodgkinson et al, 1993; Steingrimsson
et al, 1994). In the mouse, mutations at the mi locus lead to coat
color dilution, white spotting, or complete loss of pigmentation
due to absence of melanocyte (Hodgkinson et al, 1993; Hughes
et al, 1993). Similarly, in humans, mutations in MITF have been
linked to abnormal pigmentation observed inWaardenburg syn-
drome type IIa (Hughes et al, 1994; Tassabehji et al, 1994). Interest-
ingly, the cAMP/PKA pathway, through phosphorylation and
activation of the cAMP response element binding protein
(CREB) transcription factor, upregulates the Mitf promoter ac-
tivity, thereby leading to stimulation of MITF expression.
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Further, we have previously reported that Mitf is absolutely re-
quired to mediate the melanogenic e¡ects of cAMP (Bertolotto
et al, 1998a), indicating that Mitf is also crucial for melanocyte
di¡erentiation and melanogenesis.
Focusing our interest on the molecular mechanisms involved
in the regulation of melanin synthesis by cAMP, we have already
reported that cAMP promotes an inhibition of the phosphatidy-
linositol-3 kinase (PI3K) activity (Busca et al, 1996). PI3K is a li-
pid kinase that has been implicated in several physiologic
processes, such as proliferation, survival, intracellular tra⁄c, and
cell di¡erentiation (Katso et al, 2001). Additionally, a speci¢c inhi-
bitor of PI3K, LY294002, mimics the e¡ects of cAMP leading to
the induction of melanogenesis and melanocyte di¡erentiation
(Busca et al, 1996). These observations suggest that inhibition of
PI3K is an important step of cAMP-induced pigment production.
In this study, we have investigated how the inhibition of PI3K
promotes an induction of melanogenesis. First, we show that the
inhibitor of PI3K, LY294002, increases the expression of tyrosi-
nase and Tyrp1 through a transcriptional mechanism. Further, a
dominant negative form of Mitf strongly reduces the stimulation
by LY294002 of the tyrosinase and Tyrp1 promoter activities, de-
monstrating the involvement of Mitf in the regulation of mela-
nogenic enzyme transcription by LY294002.We next observed an
increased Mitf binding to the M-box sequence of the tyrosinase
and Tyrp1 promoters following LY294002 treatment, which re-
sults from a stimulation of Mitf expression. Finally, our results
indicate that elevation of Mitf levels by LY294002 is regulated at
the transcriptional level through distal regulatory elements that
remain to be identi¢ed.
MATERIALS AND METHODS
Materials Forskolin, sodium £uoride, sodium orthovanadate, 4 -(2-
aminoethyl)-benzene-sulfonyl £uoride (AEBSF), aprotinin, and leupeptin
were purchased from Sigma (Sigma Chem Co. St. Louis, MO).
LY294002 was from MERCK Eurolab (Darmstadt, Germany). Dulbecco’s
modi¢ed Eagle’s medium, trypsin, and lipofectamine reagent were from
Invitrogen (San Diego, CA) and fetal bovine serum was from Hyclone
(Logan, UT). All clinical studies were approved by the IRB for animal
use and patient consent forms were signed.
Antibodies The monoclonal anti-MITF antibody was from Dr D.
Fisher (Boston, Massachusetts). The rabbit polyclonal anti-tyrosinase (pep
7) and anti-Tyrp1 (pep1) antibodies were from Dr V. Hearing (Bethesda,
Maryland). The polyclonal phospho-speci¢c AKT (S473), CREB (S133),
p42/44 mitogen-activated protein kinase (Thr202/Tyr204), and b-catenin
(S33/S37/T41) antibodies were from Cell Signaling (Cell Signaling
Technology, Beverly, MA) and the monoclonal ERK2 (D-2) antibody
was from Santa Cruz (Santa Cruz Biotech, Santa Cruz, CA). The
phospho-glycogen synthase antibody (Ab-1) and the phospho-speci¢c Tau
antibody (S396) were purchased from Oncogene Research Products
(Darmstadt, Germany). Horseradish peroxidase or £uorescein
isothiocyanate-conjugated anti-rabbit or anti-mouse antibodies were from
Dakopatts (Glostrup, Denmark).
Methods
Cell cultures B16/F10 murine melanoma cells were grown at 371C under
5% CO2 in Dulbecco’s modi¢ed Eagle’s medium supplemented with 7%
fetal bovine serum and penicillin (100 U per mL)/streptomycin (50 mg per
mL).
Melanin content determination B16 were seeded in six-well dishes and ex-
posed to 20 mM forskolin, or LY294002 for the concentration and time in-
dicated in the ¢gure legends. Then, melanins were solubilized in 0.5 M
NaOH for 1 h at 651C. Absorbance at 405 nm was compared with a stan-
dard curve of known concentrations of fungal melanin prepared in a ¢nal
NaOH concentration of 0.5 M. The melanin content was corrected by the
total cell number of the dish and expressed as fold stimulation of melanin
of control cells.
Western blot assays B16 melanoma cells were grown in six-well dishes with
forskolin or LY294002. Cells were lyzed in bu¡er containing 50 mM Tris
pH 7.4, 150 mM NaCl, 1% Triton X-100, 10 mM leupeptin, 1 mM AEBSF,
100 U per mL aprotinin, 10 mM NaF, and 1mM Na3VO4. Samples (30 mg)
were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, transferred to a nitrocellulose membrane and then exposed to the
appropriate antibodies. Proteins were visualized with the enhanced chemi-
luminescence system from Amersham using horseradish peroxidase-conju-
gated anti-rabbit or anti-mouse secondary antibody.
Expression vectors, transfection, and luciferase assays The luciferase reporter
plasmids pTyro, pTyrp1, and pMITF and the expression vector encoding
the wild-type or the dominant negative form of MITF were previously
described (Bertolotto et al, 1998a, c). TOPFlash luciferase reporter plasmid,
containing 3 Lef/TCF binding site cloned upstream of the c-fos promoter,
was a kind gift of Dr L. Larue (Orsay, France).
Brie£y, B16 melanoma cells were seeded in 24-well dishes and transient
transfections were performed the following day using 2 mL of lipofecta-
mine and 0.5 mg of total DNA plasmid. pCMVbGal was transfected with
the test plasmids to control the variability in transfection e⁄ciency. After
48 h, cells were harvested in 50 mL of lysis bu¡er and assayed for luciferase
and b-galactosidase activities. All transfections were repeated at least three
times and performed in triplicate.
Northern blot analysis Poly(A)þ RNAwere isolated from control and for-
skolin or LY294002-treated cells using the mRNA puri¢cation kit from
Qiagen Inc.,Valencia, CA. (OligotexTM, mRNA) and total RNAwas iso-
lated by a modi¢cation of the method of Chomczynski and Sacchi (1987).
RNAwas denatured for 5 min at 651C in a formamide/formaldehyde mix-
ture, separated by electrophoresis in a 1% agarose/7% formaldehyde gel,
transferred to a nylon membrane (Hybond N, Amersham Bio Sciences,
Orsay, France) in 20 sodium citrate/chloride bu¡er (3 M NaCl, 0.3 M so-
dium citrate pH 7) and hybridized to MITF and GAPDH probe labeling
by random priming with a-[32P] deoxycytidine triphosphate (Amersham).
Immuno£uorescence studies B16 melanoma cells were grown on glass cover-
slips (2104 cells per point) in 12-well dishes and treated for 6 h with 20
mM forskolin or 10 mM LY294002. Cells were then washed, ¢xed at room
temperature for 20 min with 3% paraformaldehyde, and permeabilized by
a 2 min treatment with phosphate-bu¡ered saline 1% Triton before being
exposed to an anti-MITF antibody for 1 h at room temperature. Cells were
next incubated with FITC coupled anti-mouse antibody for 1 h at room
temperature and the cells were washed with phosphate-bu¡ered saline in
which bisbenzidine (0.5 mg per mL) was added. Finally, coverslips were
mounted in moviol immuno£uorescence mounting medium and exam-
ined with the 40 objective using Zeiss Axiophot microscope equipped
with epi£uorescence illumination.
Nuclear extracts and gel mobility shift assay Nuclear extracts from control
cells or cells incubated with 20 mM forskolin or 10 mM LY294002 were pre-
pared as previously described. Double-stranded synthetic M-box, 50 -
GAAAAAGTCATGTGCTTTGCAGAAGA-30 was g32P end-labeled using
T4 polynucleotide kinase. Five micrograms of nuclear proteins were prein-
cubated in a binding bu¡er containing 10 mMTris pH 7.5, 100 mMNaCl, 1
mM dithiothreitol, 1 mM ethylenediamine tetraacetic acid, 4% glycerol, 80
mg per mL of salmon sperm DNA, 0.1 mg poly(dIdC), 10% fetal bovine
serum, 2 mM MgCl2, and 2 mM spermidine for 15 min on ice. Then,
30,000 to 50,000 cpm of 32P-labeled probe were added to the binding reac-
tion for 10 min at room temperature. DNA-protein complexes were re-
solved by electrophoresis on a 4% polyacrylamide gel (37.5:1 acrylamide/
bisacrylamide) in TBE bu¡er (22.5 mM Tris-borate, 0.5 mM ethylenedia-
mine tetraacetic acid, pH 8) for 90 min at 100 V. For supershift assays, 0.3
mL of preimmune serum or anti-MITF antibody were preincubated with
nuclear extracts in the binding reaction bu¡er before adding the labeled
probe.
RESULTS
LY294002 increases tyrosinase and Tyrp1 expression through
a transcriptional mechanism In this study, we investigated
the molecular mechanisms by which the inhibition of the PI3K
pathway stimulates melanogenesis. With this aim we used
LY294002, a pharmacologic inhibitor of PI3K that binds to the
adenosine triphosphate binding site of PI3K and speci¢cally
blocks the activity of this kinase. In Fig 1(A), we showed that
LY294002 inhibited the phosphorylation of AKT that is a direct
target of PI3K; however, LY294002 did not a¡ect the phos-
phorylation of p42/44 mitogen-activated protein kinase or
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CREB transcription factor. These results indicate that LY294002
speci¢cally inhibits the PI3K signaling but has no e¡ect on the
p42/44 mitogen-activated protein kinase or PKA pathways.
Dose-response and time course experiments revealed a maximal
induction of melanin synthesis after 48 h of cell exposure to 10
mM of LY294002 (Fig 1B). Melanin synthesis assays were
corrected by the total cell number as forskolin and LY294002
decreased cell growth by about 22%71% and 30%73%,
respectively. Next, dose-response and time course assays of the
LY294002 e¡ects on tyrosinase and Tyrp1 were performed.
Consistent with previous observations, western blot experiments
revealed a maximal stimulation of tyrosinase and Tyrp1
expression after cell treatment with 10 mM of LY294002 for 48 h
(Fig 1C). These observations were not due to di¡erences in
loading as shown by ERK2 detection. Then, plasmids con-
taining a fragment of the tyrosinase or Tyrp1 promoter, cloned
upstream of the luciferase reporter gene, were transiently
transfected in B16 cells. Cells were incubated with LY294002,
and luciferase activity, re£ecting the activity of the promoters,
was measured.We observed that LY294002 induced a 5- and 4-
fold stimulation of the transcriptional activity of the tyrosinase and
Tyrp1 promoters, respectively (Fig 1D). As a control, we used
forskolin, which has been described to increase the expression of
tyrosinase and Tyrp1 through a transcriptional mechanism
(Fig 1B,C). Taken together, our results show that inhibition of
PI3K upregulates the transcriptional activity of the tyrosinase and
Tyrp1 promoters, thereby leading to stimulation of tyrosinase and
Tyrp1 expression and induction of melanogenesis.
MITF is a key e¡ector of LY294002-induced melanogenesis
Mitf, that plays a central role in melanocyte fate and
di¡erentiation, has been demonstrated to be an essential signal
transducer in cAMP-induced melanogenesis.We thus studied the
involvement of this transcription factor in the regulation of
melanogenesis by LY294002. The e¡ect of a dominant negative
form of Mitf, lacking the N-terminal transactivation domain
(Mi-DNT), was assayed on the response of the tyrosinase and
Tyrp1 promoters to LY294002. We showed that the Mi-DNT
transfection strongly reduced the sensitivity of the tyrosinase and
Tyrp1 promoters to LY294002, which indicates the important role
of Mitf in LY294002-induced melanogenic gene expression (Fig
2A). We next performed gel shift experiments using as labeled
probe the M-box, which is the target sequence of Mitf in the
tyrosinase and Tyrp1 promoters, respectively (Fig 2B). Nuclear
extracts from control cells formed complexes with the labeled
M-box (lane 1), that were greatly increased when reactions were
Figure1. LY294002 increases tyrosinase and Tyrp1 expression by
regulating their promoter activities. (A) Thirty micrograms of protein
extracts from unstimulated cells or cells incubated with LY294002 for
1 h were submitted to immunoblotting using phospho-speci¢c AKT
(p-AKT), phospho-speci¢c CREB (p-CREB), phospho-speci¢c ERK
(p-ERK) antibodies, or antibody that recognizes total ERK2. Molecular
masses, indicated on the left, are expressed in kilodaltons. (B) Melanin con-
tent from control B16 melanoma cells or B16 cells exposed to 20 mM for-
skolin (Fsk) or LY294002 (LY) at the concentration and times indicated on
the ¢gure, was determined as described inMaterials and Methods. Results are
expressed as fold stimulation of melanin detected in control cells. Results
are mean7SEM of three independent experiments. (C) Cells were treated
as in (B) and then 30 mg of protein extracts were subjected to western blot
analysis using the pep7 and pep1 antibodies for, respectively, tyrosinase and
Tyrp1 detection. Even loading of each lane was ensured by ERK2 detec-
tion. (D) B16 cells were transiently transfected with 0.3 mg of the luciferase
reporter plasmid pTyr or pTyrp1 and cells were left untreated or treated for
48 h with 20 mM forskolin (Fsk) or 10 mM LY294002 (LY). Then, luciferase
activity was measured and the results are expressed as fold stimulation of
the basal luciferase activity from control cells. Data are mean7SEM of
three experiments performed in triplicate.
Figure 2. MITF mediates the e¡ect of LY294002 on tyrosinase and
Tyrp1 promoter activities. (A) B16 cells were transiently transfected
with 0.3 mg of the luciferase reporter plasmid pTyro or pTyrp1 with or
without 0.05 mg of pCDNA3 encoding Mi-DNT. Cells were exposed to
LY294002 10 mM for 48 h. Luciferase activity was normalized by the
b-galactosidase activity and the results were expressed as fold stimulation
of the basal luciferase activity from control cells. Data are mean7SEM of
three experiments performed in triplicate. (B) Gel shift assays were de-
signed using the 32P-labeled M-box and B16 nuclear extracts from control
cells or cells exposed 4 h to 20 mM forskolin (Fsk) or 10 mM LY294002
(LY). In lanes 1, 3, and 5, 0.3 mL of preimmune serum and in lanes 2, 4,
and 6, 0.3 mL of a speci¢c anti-microphthalmia serum was added to the
reaction.
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performed with nuclear extracts from forskolin (lane 3) or
LY294002 (lane 5) treated cells. These complexes were strongly
displaced by a monoclonal anti-MITF antibody (lanes 2, 4, and 6),
demonstrating the speci¢c interaction of Mitf with the labeled
M-box. Together, our results indicate that the LY294002-
increased Mitf binding to its target sequence leads to a
stimulation of tyrosinase andTyrp1 gene expression.
LY294002 upregulates the expression of MITF Immuno-
£uorescence studies with the monoclonal anti-MITF antibody
showed that forskolin or LY294002 increased the level of Mitf
compared with nontreated cells (Fig 3A). On the other hand,
no change in Mitf cellular localization could be detected. Phase
contrast microscopy analysis showed, as previously described,
that forskolin or LY294002 dramatically increased B16 mela-
noma cell dendricity. Next, western blot experiments using the
monoclonal anti-MITF antibody were carried out to deter-
mine the e¡ects of PI3K inhibition on Mitf expression. Mitf,
appeared as a doublet in control cells, which was increased after
LY294002 exposure (Fig 3B). Stimulation of Mitf expre-
ssion by LY294002 or forskolin reached its maximum levels
after 4 h to 8 h of treatment. Noteworthy, stimulation of Mitf
expression by forskolin appeared more sustained than that
evoked by LY294002. Finally, we investigated how LY294002
upregulated Mitf expression. Northern blot experiments
revealed that LY294002, like forskolin, increased Mitf mRNA
levels (Fig 4A, upper panel). The equal loading of each lane was
shown by GAPDH detection (Fig 4A, lower panel). Further, the
e¡ect of actinomycin D, an inhibitor of the transcriptional
processes, was assayed on the regulation of Mitf mRNA by
forskolin and LY294002.We observed that incubation of control
B16 melanoma cells with actinomycin D decreased Mitf mRNA
below the basal level. As expected, actinomycin D completely
abolished the induction of Mitf mRNA by forskolin (Fig 4B,
upper panel). Additionally, actinomycin D totally blocked the
stimulation of the Mitf mRNA evoked by LY294002, indicating
that LY294002 as well as forskolin stimulate Mitf gene
transcription rather than Mitf messenger stability. These
observations were not due to a di¡erence in loading as shown
by the bromide ethidium staining of the 28S and 18S RNA
(Fig 4B, lower panel). In conclusion, these results demonstrate
that LY294002 increases Mitf mRNA through a transcriptional
process.
LY294002 does not activate the 2.1 kb fragment of the MITF
promoter cAMP elevating agents upregulate the activity of the
Mitf promoter through phosphorylation and activation of the
CREB transcription factor. As shown in Fig 1(A) LY294002
did not promote CREB phosphorylation. Further, we have
recently demonstrated that LY294002 and forskolin lead to the
activation of the downstream AKT target, glycogen synthase
kinase 3 b (GSK3b). Then, activated GSK3b phosphorylates
its substrates such as b-catenin, glycogen synthase, and tau
(Fig 5A,B). b-catenin, is one of the factors that controls Mitf
transcription. LY294002, however, did not a¡ect the intracellular
levels of b-catenin or the activity of aTOPFlash reporter plasmid.
These observations preclude a possible involvement of b-catenin/
Lef complex in Mitf activation by LY294002 (Fig 5A). Next,
B16 cells were transiently transfected with a reporter plasmid
containing a 2.1 kb fragment of the Mitf promoter upstream of
the luciferase gene and then were incubated with LY294002 (Fig
5C). A time course experiment indicated that LY294002 had
no e¡ect on the activity of the Mitf promoter, compared
with forskolin, which caused, as previously described, a 7-fold
stimulation of this promoter activity. These observations indicate
that LY294002 does not act on the proximal region of the Mitf
Figure 3. LY294002 increases MITF expression. (A) Immuno£uores-
cence labeling of unstimulated cells or cells treated with 20 mM forskolin
(Fsk) or to 10 mM LY294002 (LY) was designed with the monoclonal anti-
MITF antibody. (B) Thirty micrograms of protein extracts from control
cells or cells incubated with 20 mM forskolin (Fsk) or 10 mM LY294002
(LY) for the indicated times were submitted to western blot analysis using
a monoclonal anti-MITF antibody. Molecular masses, indicated on the left,
are expressed in kilodaltons.
Figure 4. LY294002 controls MITF transcription. (A) mRNA from
control B16 cells or cells exposed for 2 h to 20 mM forskolin or 10 mM
LY294002 were analyzed by Northern blot using MITF and GAPDH
probes. (B) B16 cells were left untreated or were incubated with actinomy-
cin D 2.5 mg per mL before adding 20 mM forskolin or 10 mM LY294002
for 2 h. Then, total mRNAwas extracted and analyzed by Northern blot
using MITF and GAPDH probes.
834 KHALED ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
promoter and, suggest that LY294002 regulates Mitf transcription
through distal regulatory elements.
DISCUSSION
In a previous study, it was shown that cAMP, a potent inducer of
melanogenesis, promotes an inhibition of the PI3K, and that
LY294002, a speci¢c inhibitor of PI3K, increases melanin synth-
esis (Busca et al, 1996). To investigate how inhibition of PI3K sti-
mulates pigment production, we studied the e¡ects of LY294002
on di¡erent parameters of melanin synthesis.
In this study, we ¢rst show that LY294002, by regulating the
activity of the tyrosinase andTyrp1 promoter activities leads to an
increase in tyrosinase and Tyrp1 expression and stimulation of
melanogenesis.
Further, we demonstrate that Mitf, a transcription factor that
plays a key role in melanocyte survival and di¡erentiation
(Hodgkinson et al, 1993; Steingrimsson et al, 1994; McGill et al,
2002) is implicated in the responsiveness of the melanogenic
gene promoters to LY294002. Finally, our results indicate that
LY294002 stimulates Mitf expression through a transcriptional
mechanism that involves distal regulatory elements. Indeed,
Northern blot experiments revealed that LY294002 increases Mitf
mRNA levels in B16 melanoma cells. Further, actinomycin D, an
inhibitor of transcription, prevents LY294002-induced upregula-
tion of Mitf mRNA, suggesting that LY294002 regulates Mitf
expression at the transcriptional level. To understand how
LY294002 controls Mitf transcription, we focused our attention
on the CREB transcription factor. First, we have previously re-
ported that phosphorylation and activation of CREB transcrip-
tion factor by PKA stimulates Mitf expression (Bertolotto et al,
1998a). Secondly, AKT, a downstream target of PI3K, has been
shown to promote the phosphorylation and activation of the
phosphodiesterase 3B (PDE3B), which down-modulates the in-
tracellular cAMP content (Kitamura et al, 1999). Thus, it was
tempting to hypothesize that LY294002, through the inhibition
of the PI3K/AKT/PDE3B cascade, maintained high intracellular
cAMP levels, thereby leading to PKA activation, CREB phos-
phorylation, and stimulation of the Mitf promoter activity;
however, we show that LY294002 does not a¡ect CREB
phosphorylation, demonstrating that CREB is not implicated in
the regulation of Mitf transcription by LY294002. Next, we fo-
cused our attention on b-catenin, which has been involved in
Mitf activation through its interaction with the transcription fac-
tors of the Lef/TCF family.We observed that LY294002 induces
the phosphorylation of b-catenin; however, LY294002 does not
signi¢cantly a¡ect the activity of a TOPFlash reporter plasmid
that is controlled by the b-catenin/Lef/TCF complex, meaning
that phosphorylation of b-catenin by LY294002 is not su⁄cient
to induce its degradation.We thus hypothesized that, LY294002
could trigger another regulatory element in the Mitf promoter.
Sox10 and Pax3 transcription factors have been shown to play an
important part in Mitf promoter activity, indicating that these
factors could be potential targets of LY294002 action (Watanabe
et al, 1998;Takeda et al, 2000b;Verastegui et al, 2000). A 2.1 kb frag-
ment of the Mitf promoter containing such regulatory sequences,
however, was not stimulated by LY294002, demonstrating that
the proximal regulatory region does not mediate the response of
the Mitf promoter to LY294002. Recently, a distal regulatory re-
gion located 14.5 kb upstream from exon 1 of the human MITF
gene has been shown to enhance the activity of theMitf promoter
(Watanabe et al, 2002). These data are in agreement with the pre-
sence of crucial regulatory elements upstream of the 2.1 kb frag-
ment of theMitf promoter and suggest that these sequences could
mediate the sensitivity of the Mitf promoter to LY294002. Mitf
has been shown to be the target of di¡erent signaling pathways
that regulate pigment production (Bertolotto et al, 1998a, b; Price
et al, 1998; Kim et al, 2002). Interestingly, our results demonstrate
that Mitf is also a convergence point of the PI3K pathway, thus
reinforcing the key role of Mitf in melanocyte di¡erentiation
and melanogenesis. Furthermore, we have recently shown that
cAMP, through AKT inhibition, activates the GSK3b, and inhi-
bition of GSK3b by lithium decreases forskolin-induced tyrosi-
nase promoter activity (Khaled et al, 2002). In agreement with
the report fromTakeda et al (2000a), we proposed that activation
of GSK3b by cAMP would lead to phosphorylation of Mitf, thus
increasing its binding to the M-box sequence in the tyrosinase and
Tyrp1 promoters, respectively.Therefore, the PI3K pathway stimu-
lates melanogenesis by at least two mechanisms. First, cAMP,
through inhibition of PI3K and AKT, and activation of GSK3b,
stimulates Mitf binding to the M-box of the tyrosinase promoter,
increasing the melanogenic enzyme expression (Khaled et al,
2002). Second, LY294002 would control the activity of the Mitf
promoter through distal regulatory elements that remain to be
identi¢ed.
Interestingly, forskolin gives rise to a more important and sus-
tained expression of Mitf compared with the LY294002 treat-
ment. Taken together, our results suggest that forskolin mediates
its e¡ects through the combined activation of the PKA/CREB
pathway and inhibition of PI3K, whereas LY294002 action is
only the result of PI3K inhibition. The report from Khaled et al
(2002), mentioned that cAMP inhibits AKT in a PKA-indepen-
dent manner reinforcing the notion that PKA and PI3K regulate
melanogenesis through separate pathways.These di¡erences could
explain why forskolin is a stronger inducer of tyrosinase andTyrp1
promoter activities. It should be noted, however, that the e¡ects
of forskolin and LY294002 on tyrosinase and Tyrp1 expression
and melanin synthesis were roughly comparable, suggesting that
Figure 5. Involvement of distal regulatory element in the response
to LY294002 of the MITF promoter. (A) Thirty micrograms of protein
samples from B16 melanoma cells nonstimulated or incubated for 1 h with
20 mM forskolin (Fsk) or 15 mM LY294002 (LY) were subjected to western
blot analysis using a phospho-speci¢c b-catenin (p-b-cat) antibody or an
antibody that recognizes total b-catenin (b-cat). B16 cells were transiently
transfected with aTOPFlash reporter plasmid and exposed to LY294002 48
h. Luciferase activity was normalized by the b-galactosidase activity and
the results were expressed as fold stimulation of the basal luciferase activity
from control cells. Data are mean7SEM of three experiments performed
in triplicate. (B) Protein samples of cells treated as in (A) were submitted
to immunoblotting using phospho-speci¢c glycogen synthase (p-GS) or
phospho-speci¢c Tau (p-Tau) antibodies or antibody that recognizes
ERK2 independently of its phosphorylation state. Molecular masses, indi-
cated on the left, are expressed in kilodaltons. (C) B16 cells were transfected
with 0.3 mg of the luciferase reporter plasmid pMITF and then exposed to
20 mM forskolin (Fsk) for 48 h or to 10 mM LY294002 (LY) for the indi-
cated times. Luciferase activity was normalized by the b-galactosidase ac-
tivity and the results were expressed as fold stimulation of the basal
luciferase activity from unstimulated cells. Data are mean7SEM of three
experiments performed in triplicate.
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LY294002 could also control melanogenesis through post-tran-
scriptional modi¢cations of tyrosinase or Tyrp1. Post-transcrip-
tional modi¢cations of tyrosinase and Tyrp1 have already been
proposed to upregulate their enzyme activity (Imokawa and Mis-
hima, 1982; Martinez-Esparza et al, 1998; Park et al, 1999). Whe-
ther LY294002 could promote such modi¢cations remains to be
elucidated.
In conclusion, we demonstrate in this study that the PI3K in-
hibitor, LY294002, increases Mitf expression, leading to a stimu-
lation of tyrosinase and Tyrp1 expression and ¢nally induction of
melanogenesis. Our data suggest that activation of the PKA/
CREB cascade and inhibition of PI3K during cAMP-induced
melanogenesis cooperate to trigger a stronger induction of mela-
nin synthesis. Taken together, our results bring new information
on the molecular mechanisms involved in the cAMP-induced
melanogenesis and help in the understanding of the signaling
events that govern pigmentation.
This work was supported by INSERM,The Ligue Nationale contre le Cancer and
the Association pour la Recherche sur le Cancer grant 5808.
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